Protective effect of miR378* on doxorubicin‐induced cardiomyocyte injury via calumenin. Issue 10 (17th April 2018)

• Record Type: Journal Article
• Authors: Wang, Yu; Cui, Xiaoxue; Wang, Yilin; Fu, Yao; Guo, Xin; Long, Jie; Wei, Chengxi; Zhao, Ming
• Is Part Of: Journal of cellular physiology. Volume 233:Issue 10(2018:Oct.)
• Page Start: 6344
• Page End: 6351
• Publication Date: 2018-04-17
• Subjects: apoptosis -- calumenin -- doxorubicin -- ERS -- miR378*; Physiology -- Periodicals; Cell physiology -- Periodicals; 571.6
• DOI: 10.1002/jcp.26615
• Languages: English
• ISSNs: 0021-9541

Abstract

Abstract : Doxorubicin (Dox) is a highly effective antitumor antibiotic, however myocardial toxicity severely limits its use clinically. The pathogenesis of doxorubicin‐induced cardiomyopathy is unclear. In Dox cardiomyopathy mice, there is a decline in cardiac function, a change in myocardial pathology and a reduction in miR378* expression. Expression changes in calumenin, an endoplasmic reticulum stress (ERS) chaperone protein and pathway factor, as well as apoptosis, were observed in cardiomyocytes after doxorubicin‐induced injury. However, miR378* increased calumenin expression, eased ERS, and reduced cardiomyocyte apoptosis, while, silencing miR378* reduced calumenin expression, aggravated ERS, and increased cardiomyocyte apoptosis. The above results indicate that miR378* alleviates ERS and inhibits the activation of the ERS‐mediated apoptosis signaling pathway in cardiomyocytes via regulating calumenin expression, thereby reducing cardiomyocyte apoptosis after doxorubicin‐induced injury. Increasing miR378* expression may be a new way to improve cardiac function and quality of life in patients with Dox cardiomyopathy. Abstract : miR378* alleviates ERS‐mediated apoptosis signaling pathway in cardiomyocytes via regulating calumenin expression, thereby reducing cardiomyocyte apoptosis after doxorubicin‐induced injury. Increasing miR378* expression may be a new way to improve cardiac function and quality of life in patients with doxorubicin cardiomyopathy.